Abstract 963P
Background
CRISP is a non-interventional, prospective, multi-center clinical research platform to understand the treatment reality of patients (pts) with lung cancer in Germany. Locally advanced non-small cell lung cancer (NSCLC) is a heterogenous group with several treatment approaches possible. Here we present data of pts treated with radiochemotherapy (RTCTx) in routine care in Germany.
Methods
Since August 2018 106 sites in Germany have recruited more than 1400 patients diagnosed with NSCLC stage I, II or III. Detailed patient and tumor characteristics, treatment strategies, outcome and PRO data are collected and analyzed. Here we present data on 270 pts treated with RTCTx for locally advanced NSCLC and followed until 30 June 2021.
Results
Overall, most of the pts treated with RTCTx received simultaneous RTCTx (44% with and 44% without induction chemotherapy). 12% of the pts were treated with sequential RTCTx. The most common chemotherapy regimen within the RTCTx treatment was the doublet cisplatin+vinorelbine (n=100, 37%). Out of 485 pts diagnosed with stage III and followed for at least one year (236 pts stage IIIA, 249 pts stage IIIB/C), 27% (n=64) of pts with stage IIIA and 53% (n=131) of pts with stage IIIB/C received definitive RTCTx. The median progression-free survival for pts treated with RTCTx was 10.4 months (95% CI 7.2-12.2, stage IIIA) and 9.2 months (95% CI 6.8-11.2, stage IIIB/C). The median overall survival was 21.5 months (95% CI 15.1-29.6, stage IIIA) and 22.9 months (95% CI 19.7-NA, stage IIIB/C). 80% (n=131) of pts with a non-resectable stage III tumor who received RTCTx (n=164) were tested for PD-L1 expression. 80 pts had positive PD-L1 expression, which corresponds to 49% of all pts and 61% of tested pts. Of 68 durvalumab-eligible pts (best response CR/PR/SD), 44 received consolidation therapy with durvalumab.
Conclusions
RTCTx is a well-established treatment in routine care for pts with locally advanced NSCLC in Germany. The vast majority of pts receive a platin-doublet and simultaneous RTCTx according to the guidelines. With longer follow up the impact of consolidation therapy in real-world will be analyzed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AIO-Studien-gGmbH.
Funding
CRISP satellite NSCLC stage I-III is supported by grants from AstraZeneca GmbH, Bristol-Myers Squibb GmbH & Co.KGaA, MSD SHARP & DOHME GMBH and Roche Pharma AG.
Disclosure
W.E.E. Eberhardt: Financial Interests, Personal, Advisory Role: AstraZeneca, BMS, Roche, MSD, Pfizer, Novartis, Takeda, Sanofi-Aventis, Amgen, Boehringer Ingelheim, Bayer, Johnson & Johnson, Eli Lilly; Financial Interests, Institutional, Research Grant: AstraZeneca, Eli Lilly, BMS. M. Stuschke: Financial Interests, Personal, Advisory Board: AstraZeneca, Bristol-Myers Squibb, Sanofi-Aventis, Janssen-Cilag; Financial Interests, Institutional, Research Grant: AstraZeneca. P. Christopoulos: Financial Interests, Personal, Advisory Role: AstraZeneca, Boehringer-Ingelheim, Chugai, Daiichi Sankyo, Gilead, Novartis, Pfizer, Roche, Takeda; Financial Interests, Personal, Research Grant: Amgen, AstraZeneca, Boehringer-Ingelheim, Merck, Novartis, Roche, Takeda. M. Reck: Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, BeiGene, BMS, Boehringer-Ingelheim, Daiichii-Sankyo, Merck, MSD, Lilly, Mirati, Novartis, Pfizer, Sanofi, Roche; Financial Interests, Personal, Expert Testimony: Amgen; Financial Interests, Personal, Advisory Role: AstraZeneca, BeiGene, BMS, Boehringer-Ingelheim, Daiichii-Sankyo, Merck, MSD, Lilly, Mirati, Novartis, Pfizer, Sanofi, Roche. P. Ludwig: Financial Interests, Institutional, Research Grant: Amgen Ltd., AstraZeneca GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Bristol-Myers Squibb GmbH & Co. KGaA, Celgene GmbH, MSD Sharp & Dohme GmbH, Lilly Deutschland GmbH, Novartis Pharma GmbH, Pfizer Pharma GmbH, Roche Pharma AG, Takeda Pharma Vertriebs GmbH & Co. KG, Janssen-Cilag GmbH. A. Hipper: Financial Interests, Institutional, Research Grant: Amgen Ltd., AstraZeneca GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Bristol-Myers Squibb GmbH & Co. KGaA, Celgene GmbH, MSD Sharp & Dohme GmbH, Lilly Deutschland GmbH, Novartis Pharma GmbH, Pfizer Pharma GmbH, Roche Pharma AG, Takeda Pharma Vertriebs GmbH & Co. KG, Janssen-Cilag GmbH. D.C. Christoph: Financial Interests, Personal, Advisory Role: AstraZeneca, Bristol-Myers Squibb. M. Sebastian: Financial Interests, Personal, Advisory Board: AstraZeneca, Boehringer Ingelheim, Novartis, Takeda, Lilly, BMS, MSD, Merck, Johnson, Amgen; Financial Interests, Personal, Invited Speaker: Roche, GSK; Financial Interests, Institutional, Research Grant: AstraZeneca. F. Griesinger: Financial Interests, Personal, Invited Speaker: Roche, Takeda, Pfizer, Boehringer Ingelheim, Sanofi, AbbVie, AstraZeneca, Merck, Novartis, Amgen, Janssen Cilag; Financial Interests, Personal, Advisory Board: Roche, Takeda, Pfizer, Boehringer Ingelheim, Sanofi, AbbVie, AstraZeneca, Merck, Novartis, Amgen, Janssen Cilag; Financial Interests, Institutional, Research Grant: Roche, Takeda, Pfizer, Boehringer Ingelheim, Sanofi, AbbVie, AstraZeneca, Merck, Novartis, Amgen, Janssen Cilag. M. Thomas: Financial Interests, Personal, Advisory Board: Sanofi, Lilly, BMS, MSD, Rche, Boehringer, Janssen, AstraZeneca, Amgen, Novartis; Financial Interests, Personal, Invited Speaker: Sanofi, Lilly, MSD, Roche, GSK, Pfizer, Janssen, AstraZeneca, Amgen, Novartis; Financial Interests, Institutional, Advisory Board: Takeda; Financial Interests, Institutional, Invited Speaker: Takeda; Financial Interests, Institutional, Funding: Roche, Takeda, BMS, AstraZeneca, Amgen. All other authors have declared no conflicts of interest.